Thomas Qualtere, MD
Psychiatry · Albany, NYNPI 1942476916
Payments from drug & device makers
Across 1,526 payments — averaging $22.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$8K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
- AbbVie$4K
- Alkermes, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$3K
- plus $10K from 18 others
What the payments were for
- Food & beverage$33,993100%
- Education$1380%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 362 | $7,865 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 152 | $3,935 |
| AbbVie(2 entities) | 184 | $3,570 |
| Alkermes, Inc. | 105 | $2,934 |
| Otsuka America Pharmaceutical, Inc. | 142 | $2,756 |
| Teva Pharmaceuticals USA, Inc. | 111 | $2,752 |
| Neurocrine Biosciences, Inc. | 112 | $2,607 |
| Sunovion Pharmaceuticals Inc. | 100 | $1,842 |
| Neuronetics, Inc. | 37 | $1,353 |
| Vanda Pharmaceuticals Inc. | 38 | $854 |
| E.r. Squibb & Sons, L.L.C. | 34 | $806 |
| Axsome Therapeutics, Inc. | 33 | $660 |
| Lundbeck LLC | 34 | $619 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $377 |
| Bausch Health US, LLC | 21 | $367 |
| Corium, LLC | 12 | $321 |
| Indivior Inc. | 16 | $251 |
| Vertical Pharmaceuticals, LLC | 3 | $50 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| Noven Therapeutics, LLC | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Ironshore Pharmaceuticals Inc. | 1 | $32 |
| Shire North American Group Inc | 2 | $29 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$1,457
- ARISTADA$973
- SPRAVATO$957
- LYBALVI$914
- INVEGA SUSTENNA$746
- INGREZZA$484
- UZEDY$360
- NEUROSTAR TMS THERAPY SYSTEM$283
- Austedo XR$244
- ARISTADA INITIO$243
- COBENFY$237
- AUSTEDO$224
- VRAYLAR$220
- VIVITROL$125
- NEUROSTAR TMS THERAPY$123
- ABILIFY MAINTENA$121
- REXULTI$115
- LATUDA$104
How this compares
$34,131 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 47 | $174,515 |
| UzedyRisperidone | 16 | $58,685 |
| Abilify MaintenaAripiprazole | 12 | $36,227 |
| CaplytaLumateperone Tosylate | 20 | $34,311 |
| Clozapine OdtClozapine | 12 | $4,372 |
| Fluphenazine Hcl | 12 | $1,710 |
| Hydroxyzine Hcl | 20 | $537 |
| Benztropine Mesylate | 23 | $314 |
| Lithium Carbonate ErLithium Carbonate | 11 | $299 |
| Bupropion XlBupropion Hcl | 19 | $295 |
| Buspirone Hcl | 14 | $137 |
| Nortriptyline Hcl | 11 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $7,865 | $174,51547 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $2,752 | $58,68516 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $2,756 | $36,22712 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,935 | $34,31120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Albany
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.